6
Jan
2017

Amgen Wins PCSK9 Duel, Jenkins’ Parting Shot, and Obamacare’s Last Stand

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Lilly Buys Morphic, Flagship Dreams Big, and Element Challenges Illumina
Avidity Delivers, Foresite Raises $900M, & Lilly Alzheimer’s Drug Passes Scrutiny
AstraZeneca’s Big ASCO, Summit Breaks Out, & Structure’s Oral GLP-1 Advance
Merck Bets on the Eye, Merus Raises a Fortune, & Roche Leadership Change